Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie.

bladder cancer neoadjuvant preoperative prostate cancer radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
02 Dec 2021
Historique:
received: 02 11 2021
revised: 26 11 2021
accepted: 28 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

Preoperative radiotherapy (RT) is commonly used for the treatment of various malignancies, including sarcomas, rectal, and gynaecological cancers, but it is preferentially used as a competitive treatment to radical surgery in uro-oncology or as a salvage procedure in cases of local recurrence. Nevertheless, preoperative RT represents an attractive strategy to prevent from intraoperative tumor seeding in the operative field, to sterilize microscopic extension outside the organ, and to enhance the pathological and/or imaging tumor response rate. Several clinical works support this research field in uro-oncology. In this review article, we summarized the oncologic impact and safety of preoperative RT in localized prostate and muscle-invasive bladder cancer. Preliminary studies suggest that both modalities can be complementary as initial primary tumor treatments and that a pre-operative radiotherapy strategy could be beneficial in a well-defined population of patients who are at a very high-risk of local relapse. Future prospective trials are warranted to evaluate the oncologic benefit of such a combination of local treatments in addition to new life-prolonging systemic therapies, such as immunotherapy, and new generation hormone therapies. Moreover, the safety and the feasibility of salvage surgical procedures due to non-response or local recurrence after pelvic RT remain poorly evaluated in that context.

Identifiants

pubmed: 34885179
pii: cancers13236070
doi: 10.3390/cancers13236070
pmc: PMC8656987
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

J Urol. 2009 Mar;181(3):956-62
pubmed: 19167731
Eur Urol. 2021 Sep 9;:
pubmed: 34511303
Eur Radiol. 2011 Sep;21(9):1970-8
pubmed: 21533634
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):60-70
pubmed: 15337540
JAMA Surg. 2018 Jan 17;153(1):e174591
pubmed: 29188298
AJR Am J Roentgenol. 2012 Mar;198(3):596-602
pubmed: 22357998
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Cancer Treat Rev. 2018 Nov;70:88-97
pubmed: 30125800
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):391-399
pubmed: 33972025
Lancet Oncol. 2021 May;22(5):702-715
pubmed: 33862000
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):88-93
pubmed: 23790772
J Urol. 1997 Mar;157(3):805-7; discussion 807-8
pubmed: 9072571
Bladder Cancer. 2017 Jan 27;3(1):19-30
pubmed: 28149931
J Urol. 2021 Jul;206(1):29-36
pubmed: 33617327
BMC Cancer. 2020 Jan 3;20(1):8
pubmed: 31900121
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):544-53
pubmed: 26723110
Anticancer Res. 1998 May-Jun;18(3B):1931-4
pubmed: 9677446
Histol Histopathol. 2007 Jan;22(1):107-18
pubmed: 17128417
J Surg Oncol. 1977;9(4):393-405
pubmed: 330958
J Urol. 1972 Dec;108(6):875-8
pubmed: 5082739
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):930-935
pubmed: 32562839
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
Histopathology. 2012 Jan;60(1):153-65
pubmed: 22212084
Cancer. 2009 Feb 1;115(3):673-9
pubmed: 19117039
Diagn Interv Imaging. 2016 Apr;97(4):433-41
pubmed: 26928245
Eur Urol Open Sci. 2021 May;27:43-52
pubmed: 33997823
Radiother Oncol. 2021 Aug;161:95-114
pubmed: 34118357
Adv Radiat Oncol. 2018 May 08;3(3):331-338
pubmed: 30202802
J Clin Oncol. 2009 Jun 20;27(18):2924-30
pubmed: 19433689
J Magn Reson Imaging. 2018 Oct;48(4):1012-1023
pubmed: 29517822
BJU Int. 2020 Sep;126(3):367-372
pubmed: 32333714
Cancer. 2014 Apr 15;120(8):1272-80
pubmed: 24390799
Med Dosim. 2015 Winter;40(4):372-7
pubmed: 26323390
Radiology. 2013 Aug;268(2):440-50
pubmed: 23481164
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Am J Surg Pathol. 2003 Feb;27(2):206-12
pubmed: 12548167
Curr Oncol. 2021 Jul 29;28(4):2881-2892
pubmed: 34436018
Ther Adv Urol. 2021 Aug 25;13:17562872211039583
pubmed: 34457041
Lancet Oncol. 2020 Oct;21(10):1366-1377
pubmed: 32941794
Jpn J Clin Oncol. 2011 Dec;41(12):1373-9
pubmed: 21994208
World J Urol. 2021 Jun;39(6):1757-1768
pubmed: 32995918
J Urol. 2012 Feb;187(2):463-8
pubmed: 22177159
J Urol. 1980 Aug;124(2):237-9
pubmed: 7401237
Eur Urol. 2003 Mar;43(3):246-57
pubmed: 12600427
J Urol. 1995 Dec;154(6):2059-63; discussion 2063-4
pubmed: 7500458
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1168-73
pubmed: 16376486
World J Urol. 2021 May;39(5):1331-1343
pubmed: 32915313
Prog Urol. 2020 Nov;30(12S):S136-S251
pubmed: 33349424
Eur Urol. 1983;9(3):142-7
pubmed: 6861819
Urol Oncol. 2013 Apr;31(3):359-65
pubmed: 21353794
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Arch Pathol Lab Med. 2007 Mar;131(3):360-71
pubmed: 17516739
J Urol. 1985 Aug;134(2):266-8
pubmed: 3894693
Eur Urol. 2017 Jun;71(6):952-960
pubmed: 28081860
Int J Radiat Oncol Biol Phys. 1992;24(3):463-8
pubmed: 1399731
Radiother Oncol. 2008 Jul;88(1):53-60
pubmed: 18423916
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66
pubmed: 30625410
Can Urol Assoc J. 2018 Oct;12(10):351-360
pubmed: 29989916
Nat Rev Clin Oncol. 2011 Feb;8(2):107-13
pubmed: 21178999
Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):787-94
pubmed: 500410

Auteurs

Paul Sargos (P)

Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France.

Stéphane Supiot (S)

Department of Radiotherapy, Insitut de Cancérologie de l'Ouest, 44800 St-Herblain, France.

Gilles Créhange (G)

Department of Radiotherapy, Institut Curie, 75005 Paris, France.

Gaëlle Fromont-Hankard (G)

Department of Pathology, CHRU Tours, 37000 Tours, France.

Eric Barret (E)

Department of Urology, Institut Mutualiste Montsouris, 75014 Paris, France.

Jean-Baptiste Beauval (JB)

Department of Urology, La Croix du Sud Hôpital, 31130 Quint Fonsegrives, France.

Laurent Brureau (L)

Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, 97110 Pointe-à-Pitre, France.

Charles Dariane (C)

Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris-Paris University-U1151 Inserm-INEM, Necker, 75015 Paris, France.

Gaëlle Fiard (G)

Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38000 Grenoble, France.

Mathieu Gauthé (M)

Unité de Recherche Clinique en Économie de la Santé, CRESS METHODS INSERM UMR 1153, 75000 Paris, France.

Romain Mathieu (R)

Department of Urology, CHU Rennes, 35033 Rennes, France.

Guilhem Roubaud (G)

Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.

Alain Ruffion (A)

Service d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69002 Lyon, France.
Equipe 2, Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Faculté de Médecine Lyon Sud, Université Lyon 1, 69002 Lyon, France.

Raphaële Renard-Penna (R)

Department of Radiology, Sorbonne University, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France.

Yann Neuzillet (Y)

Department of Urology, Hôpital Foch, 92151 Suresnes, France.

Morgan Rouprêt (M)

Department of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hôpital, 31130 Quint Fonsegrives, France.

Classifications MeSH